Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.6%

1 terminated/withdrawn out of 28 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

36%

4 of 11 completed trials have results

Key Signals

6 recruiting4 with results

Enrollment Performance

Analytics

Early Phase 1
10(52.6%)
N/A
5(26.3%)
Phase 2
4(21.1%)
19Total
Early Phase 1(10)
N/A(5)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials
NCT04792528Not ApplicableActive Not Recruiting

REACT MCI - Repeated Advanced Cognitive Training in Mild Cognitive Impairment

Role: collaborator

NCT05940493Phase 2Recruiting

Abemaciclib in Newly Diagnosed Meningioma Patients

Role: collaborator

NCT05076513Early Phase 1Active Not Recruiting

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

Role: collaborator

NCT05182905Early Phase 1Active Not Recruiting

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

Role: collaborator

NCT04391595Early Phase 1Completed

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

Role: collaborator

NCT07454785Not ApplicableNot Yet Recruiting

Neuronal Mechanisms of Learning and Utilizing Abstract Representations

Role: collaborator

NCT02933736Early Phase 1Active Not Recruiting

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

Role: collaborator

NCT05944692Recruiting

Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)

Role: collaborator

NCT06072586Early Phase 1Recruiting

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

Role: collaborator

NCT04424966Early Phase 1Terminated

Infigratinib in Recurrent High-Grade Glioma Patients

Role: collaborator

NCT04467489Active Not Recruiting

Biomarkers of CASH

Role: collaborator

NCT03834740Early Phase 1Completed

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Role: collaborator

NCT01764529Active Not Recruiting

Modifiers of Disease Severity in Cerebral Cavernous Malformations

Role: collaborator

NCT03397004Phase 2Completed

Doxycycline for Hereditary Hemorrhagic Telangiectasia

Role: collaborator

NCT04559685Early Phase 1Recruiting

Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma

Role: collaborator

NCT04614909Early Phase 1Active Not Recruiting

Study of Pamiparib in Newly Diagnosed and rGBM

Role: collaborator

NCT05773326Early Phase 1Recruiting

Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

Role: collaborator

NCT06734286Not ApplicableRecruiting

Working Memory Training in Patients with Mild Cognitive Impairment

Role: collaborator

NCT02513914Not ApplicableSuspended

Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

Role: collaborator

NCT05305378Completed

Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow

Role: collaborator